HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aleve ad dispute

This article was originally published in The Tan Sheet

Executive Summary

McNeil's motion to preliminarily enjoin Bayer from airing "Love of the Game" TV spot for naproxen sodium denied by Newark, N.J. federal Judge Katharine Hayden. In a transcript of her Sept. 27 oral ruling, judge says she "cannot agree with McNeil that this commercial contains an unambiguous message that Aleve works better at relieving pain than Tylenol," and J&J division "has not supported its claim of literal falsity." McNeil sued Bayer in August, claiming the Aleve commercial falsely suggests naproxen "relieves more severe pain or relieves pain more effectively" than Tylenol (1"The Tan Sheet" Aug. 12, 2002, p. 4). McNeil says it has not decided whether to continue lawsuit or appeal ruling...

You may also be interested in...

McNeil, Bayer Aleve Ad Dispute Heats Up With Federal Lawsuit

McNeil Consumer & Specialty Pharmaceuticals' has taken its dispute with Bayer Consumer Care over advertising for Aleve to court, after a NAD decision apparently failed to resolve the conflict

Swiss Biotechs May Get SPAC Listing Option Soon

Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.

Novartis Q1 Preview: Profits Still Under Pressure From Lockdown

The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts